{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Tumors&page=7", "query": { "condition": "Ovarian Tumors", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 2456, "total_pages": 246, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Tumors&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Tumors&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T19:49:25.559Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00466986", "title": "Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "Abraxane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Southeastern Gynecologic Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 40, "start_date": "2005-11", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2011-10-12", "last_synced_at": "2026-10-11T19:49:25.559Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00466986" }, { "nct_id": "NCT05238922", "title": "Study of INCB123667 in Subjects With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB0123667", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 291, "start_date": "2022-07-05", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-11T19:49:25.559Z", "location_count": 18, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05238922" }, { "nct_id": "NCT00683241", "title": "A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "DCVac-L", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 36, "start_date": "2007-11", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2013-02-26", "last_synced_at": "2026-10-11T19:49:25.559Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00683241" }, { "nct_id": "NCT01997190", "title": "Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Pleural Effusion", "Lung Cancer", "Mesothelioma", "Breast Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "AdV-tk + valacyclovir", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Candel Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2013-10", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2023-08-25", "last_synced_at": "2026-10-11T19:49:25.559Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01997190" }, { "nct_id": "NCT07504588", "title": "Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma", "Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma", "Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma", "Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma", "Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma", "Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma" ], "interventions": [ { "name": "Anti-VEGF Monoclonal Antibody", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pegylated Liposomal Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Sacituzumab Govitecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 87, "start_date": "2026-09-24", "completion_date": "2029-04-12", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-11T19:49:25.559Z", "location_count": 9, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Post Falls", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT07504588" }, { "nct_id": "NCT06885697", "title": "Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mesothelioma", "Neoplasms", "Stomach Neoplasms", "Pancreatic Neoplasms", "Ovarian Neoplasms", "Lung Neoplasms", "Thymus Neoplasms", "Colonic Neoplasms" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "TNhYP218 CAR T Cells", "type": "BIOLOGICAL" }, { "name": "mesothelin expression testing", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DEVICE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 120, "start_date": "2025-07-08", "completion_date": "2044-06-01", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-11T19:49:25.559Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06885697" }, { "nct_id": "NCT00803569", "title": "Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Peritoneal Cavity Cancer" ], "interventions": [ { "name": "ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Ludwig Institute for Cancer Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 13, "start_date": "2008-11-14", "completion_date": "2011-01-24", "has_results": true, "last_update_posted_date": "2023-10-04", "last_synced_at": "2026-10-11T19:49:25.559Z", "location_count": 2, "location_summary": "Buffalo, New York • New York, New York", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00803569" }, { "nct_id": "NCT06629883", "title": "Resistance Exercise and Peer Support with Bands/balls and Digital Support Among Women with Polycystic Ovary Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Polycystic Ovary Syndrome (PCOS)" ], "interventions": [ { "name": "REPS w/BANDS", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2022-06-01", "completion_date": "2023-05-31", "has_results": false, "last_update_posted_date": "2024-10-08", "last_synced_at": "2026-10-11T19:49:25.559Z", "location_count": 1, "location_summary": "Columbia, South Carolina", "locations": [ { "city": "Columbia", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06629883" }, { "nct_id": "NCT02605083", "title": "A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "eFT508", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Effector Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2015-12-03", "completion_date": "2019-03-22", "has_results": false, "last_update_posted_date": "2020-11-02", "last_synced_at": "2026-10-11T19:49:25.559Z", "location_count": 4, "location_summary": "Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02605083" }, { "nct_id": "NCT01065662", "title": "AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Endometrial Cancer", "Ovarian Cancer", "Cervical Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "temsirolimus", "type": "DRUG" }, { "name": "cediranib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Susana M. Campos, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 11, "start_date": "2010-02", "completion_date": "2021-03", "has_results": false, "last_update_posted_date": "2021-04-21", "last_synced_at": "2026-10-11T19:49:25.559Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01065662" } ] }